English 
Francais 
عربي 
Cervical cancer: a clear round for Gardasil
[mis à jour le 23 November 2006 à 14h53]
Gardasil, the potential vaccine for cervical cancer produced by Merck & Co, has passed its examination. A new analysis of a phase II clinical trial carried out over five years showed that it provided 100% protection for the women vaccinated.
Even for those who had already been exposed to the papillomavirus before vaccination. This virus causes up to 70% of cervical cancers! These preliminary results were presented recently at the International Congress, Eurogin 2006, in Paris. The random double-blind study with placebo covered 552 women aged between 16 and 23 years.
“These are very interesting results. They provide new arguments in favour of vaccinating teenagers and young women”, said Dr Luiza Villa.
Gardasil is one of the two first candidate vaccines – with Cervarix, produced by the GSK laboratories – against cervical cancer. This long-awaited vaccine should provide protection against human papillomavirus infections (HPV) of type 6, 11, 16 and 18. It should also protect against the development of genital warts, condyloma acuminata. Source: Sanofi Pasteur MSD, 26 April 2006
Print this article
Share on Facebook
Share on Twitter
Send to a friend
Convert to pdf
Copyright Authorization
17 article(s)
Breast cancer – the finger points at smoking yet again …
Prostate cancer – keeping active is best
Breast cancer – looking at the role of the working environment
Breast implants – the risk of cancer is low
Cancer – yoga helps combat fatigue
Family pets – a great way for children to develop socially!
Diabetes – getting wise to sweet foods
The Nobel Prize for Medicine – spotlight on telomeres
Beating cancer by increasing radiotherapy effectiveness
Cancer in childhood is not necessarily a deterrent to smoking…
